132 related articles for article (PubMed ID: 35483335)
1. Epidemiology of Huntington's Disease in the United States Medicare and Medicaid Populations.
Exuzides A; Reddy SR; Chang E; Ta JT; Patel AM; Paydar C; Yohrling GJ
Neuroepidemiology; 2022; 56(3):192-200. PubMed ID: 35483335
[TBL] [Abstract][Full Text] [Related]
2. Healthcare utilization and direct medical costs of Huntington's disease among Medicaid beneficiaries in the United States.
Patel AM; Chang E; Paydar C; Reddy SR
J Med Econ; 2023; 26(1):811-820. PubMed ID: 37285853
[TBL] [Abstract][Full Text] [Related]
3. Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States.
Exuzides A; Reddy SR; Chang E; Ta JT; Patel AM; Paydar C; Yohrling GJ
J Med Econ; 2021; 24(1):1327-1336. PubMed ID: 34730477
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data.
Ohlmeier C; Saum KU; Galetzka W; Beier D; Gothe H
BMC Neurol; 2019 Dec; 19(1):318. PubMed ID: 31823737
[TBL] [Abstract][Full Text] [Related]
5. Geographic Barriers Drive Disparities in Specialty Center Access for Older Adults with Huntington's Disease.
Pham Nguyen TP; Bravo L; Gonzalez-Alegre P; Willis AW
J Huntingtons Dis; 2022; 11(1):81-89. PubMed ID: 35253771
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J
J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039
[TBL] [Abstract][Full Text] [Related]
7. Incremental value of using Medicaid claim files to study comorbid conditions and treatments in dually eligible beneficiaries.
Bradley CJ; Dahman B; Bataki PM; Koroukian S
Med Care; 2010 Jan; 48(1):79-84. PubMed ID: 20050352
[TBL] [Abstract][Full Text] [Related]
8. Disparities in Palliative Care Utilization Among Hospitalized People With Huntington Disease: A National Cross-Sectional Study.
Sokol LL; Bega D; Yeh C; Kluger BM; Lum HD
Am J Hosp Palliat Care; 2022 May; 39(5):516-522. PubMed ID: 34291654
[TBL] [Abstract][Full Text] [Related]
9. Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review.
Wexler NS; Collett L; Wexler AR; Rawlins MD; Tabrizi SJ; Douglas I; Smeeth L; Evans SJ
BMJ Open; 2016 Feb; 6(2):e009070. PubMed ID: 26908513
[TBL] [Abstract][Full Text] [Related]
10. Interventional differences among Huntington's disease patients by disease progression in commercial and medicaid populations.
Anderson KE; Divino V; DeKoven M; Langbehn D; Warner JH; Giuliano J; Lee WC
J Huntingtons Dis; 2014; 3(4):355-63. PubMed ID: 25575957
[TBL] [Abstract][Full Text] [Related]
11. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis.
Divino V; Dekoven M; Warner JH; Giuliano J; Anderson KE; Langbehn D; Lee WC
J Med Econ; 2013 Aug; 16(8):1043-50. PubMed ID: 23789925
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological Study of Huntington's Disease in the Province of Ferrara, Italy.
Carrassi E; Pugliatti M; Govoni V; Sensi M; Casetta I; Granieri E
Neuroepidemiology; 2017; 49(1-2):18-23. PubMed ID: 28803251
[TBL] [Abstract][Full Text] [Related]
13. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis.
Smoyer-Tomic KE; Amato AA; Fernandes AW
BMC Musculoskelet Disord; 2012 Jun; 13():103. PubMed ID: 22703603
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic rate estimation from Medicare records: Dependence on claim numbers and latent clinical features.
Hogans B; Siaton B; Sorkin J
J Biomed Inform; 2023 Sep; 145():104463. PubMed ID: 37517509
[TBL] [Abstract][Full Text] [Related]
15. Huntington's disease in the United States: Variation by demographic and socioeconomic factors.
Bruzelius E; Scarpa J; Zhao Y; Basu S; Faghmous JH; Baum A
Mov Disord; 2019 Jun; 34(6):858-865. PubMed ID: 30868663
[TBL] [Abstract][Full Text] [Related]
16. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis.
Pringsheim T; Wiltshire K; Day L; Dykeman J; Steeves T; Jette N
Mov Disord; 2012 Aug; 27(9):1083-91. PubMed ID: 22692795
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric comorbidities in Huntington's and Parkinson's Disease: A United States claims database analysis.
Ishihara L; Oliveri D; Wild EJ
Ann Clin Transl Neurol; 2021 Jan; 8(1):126-137. PubMed ID: 33217173
[TBL] [Abstract][Full Text] [Related]
18. Huntington's disease: current epidemiology and pharmacological management in UK primary care.
Sackley C; Hoppitt TJ; Calvert M; Gill P; Eaton B; Yao G; Pall H
Neuroepidemiology; 2011; 37(3-4):216-21. PubMed ID: 22133668
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records.
Evans SJ; Douglas I; Rawlins MD; Wexler NS; Tabrizi SJ; Smeeth L
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1156-60. PubMed ID: 23482661
[TBL] [Abstract][Full Text] [Related]
20. Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019).
Furby H; Moore S; Nordstroem AL; Houghton R; Lambrelli D; Graham S; Svenningsson P; Petersén Å
J Neurol; 2023 Feb; 270(2):864-876. PubMed ID: 36253622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
